

From Frontiers Forum:
How can research translate to R&D? Or a whole new business venture? In a panel session at Science Unlimited 2019, Holtzbrinck Publishing Group CEO Stefan von Holtzbrinck, Life Biosciences CEO Mehmood Khan, Logitech CEO Bracken Darrell and EPFL’s Henry Markram discussed innovation, R&D and successful technology transfer.
Stefan von Holtzbrinck, Holtzbrinck Publishing Group
Stefan von Holtzbrinck is CEO of the family-owned Holtzbrinck Publishing Group. He has 20 years’ experience in science communication, including 3 years as MD of Nature Publishing Group. The Holtzbrinck Publishing Group has majority holdings in Springer Nature (of which Stefan is Chairman of the Supervisory Board), Digital Science, DIE ZEIT and Macmillan, and investments in Holtzbrinck Ventures, Frontiers, AMBOSS, GSV AcceleraTE and Rethink Education fund. Stefan is a member of the Executive Committee of the Max Planck Society.
Mehmood Khan, Life Biosciences
Mehmood Khan is CEO and Board Member of Life Biosciences Inc, where he provides strategic direction and operational oversight. He was previously Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo and President of Global R&D at Takeda Pharmaceuticals. Before moving into industry, Mehmood had a distinguished medical career, including as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit.
Bracken Darrell, Logitech
Bracken Darrell is President and CEO of Logitech, the largest Swiss consumer electronics company with CHF 3 billion in annual revenues. He is responsible for the company’s strategy for growth and profitability, for the vision for the brand as well as for the company’s operations. Logitech has been a top performer on both the Nasdaq and Swiss stock exchanges. The company value has risen by over 500 percent in the past seven years as the company has moved from PC peripherals to new categories and new brands.
Henry Markram, EPFL
Henry Markram has pioneered simulation neuroscience as a new path to understanding how the brain works. As Professor of Neuroscience at the Swiss Federal Institute of Technology in Lausanne (EPFL), he founded the Brain Mind Institute, the Blue Brain Project and the Human Brain Project, a €1 Billion European initiative to simulate the brain. His research has shifted from experimentally reverse engineering neocortical tissue to developing a software ecosystem and algorithms to convert biological data into detailed digital reconstructions of brain tissue.
Image Credit: Amanda Scott – Alias Studio Sydney
News This Week
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
















Leave A Comment